Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Cordlife Group ( (SG:P8A) ).
Cordlife Group Limited is facing potential operational challenges as the Ministry of Health considers suspending its cord blood banking service license for a year. The company has conducted a going concern assessment, revealing financial pressures from fixed fees, potential refunds, and uncertain customer payments, which could impact its liquidity and operational stability.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry, focusing on cord blood banking and human tissue banking services.
YTD Price Performance: 18.67%
Average Trading Volume: 59,207
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$45.44M
See more data about P8A stock on TipRanks’ Stock Analysis page.